Page last updated: 2024-08-21

cyclopentane and carboplatin

cyclopentane has been researched along with carboplatin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berger, AJ; Bryant, JL; Conaway, MR; Dutta, A; Jazaeri, AA; Milhollen, MA; Modesitt, SC; Park, J; Shibata, E; Smith, PG	1
Custodio, DF; de Sousa, GF; Freitas, VM; Lima, Mde A; Monteiro, G	1
Bauer, TM; Faessel, H; Faller, DV; Harvey, RD; Lockhart, AC; Nemunaitis, J; Sedarati, F; Venkatakrishnan, K; Zhou, X	1

Trials

1 trial(s) available for cyclopentane and carboplatin

Article	Year
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. British journal of clinical pharmacology, 2019, Volume: 85, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines	2019

Article

Year

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

British journal of clinical pharmacology, 2019, Volume: 85, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines

2019

Other Studies

2 other study(ies) available for cyclopentane and carboplatin

Article	Year
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Molecular cancer therapeutics, 2013, Volume: 12, Issue:10 Topics: Apoptosis; Carboplatin; Cell Line, Tumor; Cisplatin; Cyclopentanes; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitination	2013
Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins. PloS one, 2015, Volume: 10, Issue:12 Topics: Carboplatin; Cell Line, Tumor; Chromosomes, Human, Pair 1; Cullin Proteins; Cyclopentanes; Drug Resistance, Fungal; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Female; Gene Expression Profiling; Humans; Mutation; Ovarian Neoplasms; Pyrimidines; Saccharomyces cerevisiae; Ubiquitin-Activating Enzymes	2015

Article

Year

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

Topics: Apoptosis; Carboplatin; Cell Line, Tumor; Cisplatin; Cyclopentanes; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitination

2013

Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins.

PloS one, 2015, Volume: 10, Issue:12

Topics: Carboplatin; Cell Line, Tumor; Chromosomes, Human, Pair 1; Cullin Proteins; Cyclopentanes; Drug Resistance, Fungal; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Female; Gene Expression Profiling; Humans; Mutation; Ovarian Neoplasms; Pyrimidines; Saccharomyces cerevisiae; Ubiquitin-Activating Enzymes

2015